Ghisallo Capital Management LLC Invests $1.24 Million in Disc Medicine, Inc. $IRON

Key Points

• Ghisallo Capital Management LLC acquired 25,000 shares of Disc Medicine, Inc. for approximately $1,241,000, increasing their stake in the company to around 0.07% as of the latest SEC filing.
• Disc Medicine has received favorable ratings from analysts, with a consensus rating of "Buy" and a target price of $98.30, indicating strong market confidence in the company's potential.
• Disc Medicine's stock performance shows significant volatility, with a 12-month low of $30.82 and a high of $68.73, while the company reported a loss of ($1.58) EPS, missing estimates.

Ghisallo Capital Management LLC acquired a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,000 shares of the company's stock, valued at approximately $1,241,000. Ghisallo Capital Management LLC owned about 0.07% of Disc Medicine as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Amalgamated Bank grew its position in Disc Medicine by 38.6% during the 1st quarter. Amalgamated Bank now owns 787 shares of the company's stock worth $39,000 after acquiring an additional 219 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after acquiring an additional 266 shares during the last quarter. Arizona State Retirement System grew its position in Disc Medicine by 12.5% during the 1st quarter. Arizona State Retirement System now owns 5,315 shares of the company's stock worth $264,000 after acquiring an additional 590 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Disc Medicine by 9.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,934 shares of the company's stock worth $344,000 after acquiring an additional 624 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in Disc Medicine during the 4th quarter worth $40,000. Institutional investors own 83.70% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on IRON shares. Morgan Stanley boosted their price objective on Disc Medicine from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Monday, August 18th. BMO Capital Markets upped their price target on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday, May 12th. HC Wainwright reiterated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Thursday, July 3rd. Raymond James Financial initiated coverage on Disc Medicine in a research report on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 price target on the stock. Finally, Truist Financial initiated coverage on Disc Medicine in a research report on Monday, July 21st. They issued a "buy" rating and a $86.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the stock. According to data from MarketBeat.com, Disc Medicine currently has an average rating of "Buy" and a consensus price target of $98.30.

Insider Transactions at Disc Medicine

In other news, Director Kevin Bitterman sold 2,287 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $61.03, for a total value of $139,575.61. Following the completion of the sale, the director directly owned 590,621 shares of the company's stock, valued at $36,045,599.63. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John D. Quisel sold 34,800 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $55.33, for a total value of $1,925,484.00. Following the completion of the sale, the chief executive officer directly owned 161,828 shares of the company's stock, valued at approximately $8,953,943.24. This trade represents a 17.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 135,909 shares of company stock valued at $8,006,371 over the last ninety days. 3.64% of the stock is currently owned by insiders.

Disc Medicine Stock Up 2.9%

IRON stock traded up $1.75 during trading on Tuesday, reaching $61.40. 356,331 shares of the stock were exchanged, compared to its average volume of 292,549. The firm's 50 day moving average is $58.05 and its 200 day moving average is $51.92. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $68.73. The company has a current ratio of 32.11, a quick ratio of 32.11 and a debt-to-equity ratio of 0.05. The firm has a market cap of $2.13 billion, a P/E ratio of -13.74 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.41). As a group, research analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.